ReviewMedical oncology (Northwood, London, England)2026
Treg-derived exosomal miR-146a orchestrates bidirectional Treg-CAF crosstalk to sustain immunosuppressive tumor microenvironments.
Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Resistance to immunotherapy is often reinforced by the resilient immunosuppressive architecture of the tumor microenvironment (TME). Although the crosstalk between regulatory T cells (Tregs) and cancer-associated fibroblasts (CAFs) is increasingly recognized as an important contributor to this resistance, the specific molecular links that sustain this interaction remain incompletely understood. This review proposes a bidirectional Treg-derived exosomal miR-146a-CAF signaling model to explain how immunosuppressive remodeling may be maintained. Current evidence suggests that activated Tregs can release exosomes enriched in miR-146a and may thereby influence the response state of recipient CAFs through signaling nodes such as TRAF6/IRAK1, NF-κB, and JAK2-STAT3. Meanwhile, CAF-derived signals may support Treg recruitment and functional maintenance. Through the secretion of chemokines and cytokines such as CCL2, CXCL12, TGF-β, and IL-6, CAFs contribute to Treg recruitment, local persistence, and suppressive function. Because these processes are currently supported largely by indirect evidence derived from different experimental models, this review integrates them into a bidirectional Treg-CAF communication framework that requires further validation, rather than presenting them as a fully established causal feedback loop. To therapeutically interrogate and potentially disrupt this putative circuit, we discuss strategies focused on blocking exosome biogenesis, neutralizing extracellular miR-146a, or disrupting downstream metabolic and signaling dependencies. These strategies are better viewed as candidate approaches for validating and intervening in this model, rather than as clinically mature targeted therapies. By distinguishing validated mechanisms from indirect evidence and testable inferences, this review aims to provide a clearer experimental framework and potential translational directions for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.